Sandy Griffith, PharmD

Director Clinical Development
ViiV Healthcare

Disclosure: GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee)

Presentation(s):

• LB-8 - Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

  Saturday, October 24, 2020
  11:00am – 11:10am EDT